

ISPAD Clinical Practice Consensus Guidelines 2014 Compendium

Other complications and diabetes-associated conditions in children and adolescents

Kordonouri O, Klingensmith G, Knip M, Holl RW, Menon PSN, Aanstoot HJ, Craig ME. Other complications and diabetes-associated conditions in children and adolescents. *Pediatric Diabetes* 2014; 15 (Suppl. 20): 270–278.

Olga Kordonouri^a, Georgeanna Klingensmith^b, Mikael Knip^c, Reinhard W Holl^d, Henk-Jan Aanstoot^e, Puthezhath SN Menon^f and Maria E Craig^{g,h,i}

^aDiabetes Centre for Children and Adolescents, Children's Hospital auf der Bult, Hannover, Germany; ^bDepartment of Pediatrics, The Children's Hospital and Barbara Davis Centre, University of Colorado, Aurora, CO, USA; ^cHospital for Children and Adolescents, University of Helsinki, Helsinki, Finland; ^dInstitute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany; ^eDiabeter Center for Pediatric and Adolescent Diabetes Care and Research, Rotterdam, the Netherlands; ^fDepartment of Pediatrics, Jaber Al-Ahmed Armed Forces Hospital, Kuwait, Kuwait; ^gInstitute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, Australia; ^hDiscipline of Pediatrics and Child Health, University of Sydney, Sydney, Australia and

ⁱSchool of Women's and Children's Health, University of New South Wales, Sydney, Australia

Key words: celiac disease – child – complications – thyroid disease – type 1 diabetes

Corresponding author: Assoc. Prof. Maria Craig,
Institute of Endocrinology and Diabetes,
The Children's Hospital at Westmead,
Locked Bag 4001,
Westmead, NSW 2145,
Australia.
e-mail: m.craig@unsw.edu.au

Editors of the ISPAD Clinical Practice Consensus Guidelines 2014 Compendium: Carlo Acerini, Carine de Beaufort, Maria Craig, David Maahs, Ragnar Hanas.

This article is a chapter in the *ISPAD Clinical Practice Consensus Guidelines 2014 Compendium*. The complete set of guidelines can be found for free download at www.ispad.org. The evidence grading system used in the ISPAD Guidelines is the same as that used by the American Diabetes Association. See page 3 (the Introduction in *Pediatric Diabetes* 2014; 15 (Suppl. 20): 1–3).

Executive summary and Recommendations

- Monitoring of growth and physical development and the use of growth charts are essential in the continuous care of children and adolescents with type 1 diabetes (E).
- Screening of thyroid function by measurement of thyroid stimulating hormone (TSH) and anti-thyroid peroxidase antibodies is recommended at the diagnosis of diabetes (A) and, thereafter, every second year in asymptomatic individuals without goiter or in the absence of thyroid autoantibodies. More frequent assessment is indicated otherwise (E).
- Screening for celiac disease should be performed at the time of diabetes diagnosis, and every 1–2 yr thereafter (B). More frequent assessment is indicated if the clinical situation suggests the possibility of celiac disease or the child has a first-degree relative with celiac disease (E).

- Screening for celiac disease is based on the detection of Immunoglobulin A (IgA) antibodies: tissue transglutaminase (tTG-A) and/or endomysial (EMA).
- Screening for IgA deficiency should be performed at diabetes diagnosis. In people with confirmed IgA deficiency, screening for celiac disease should be performed using IgG specific antibody tests (tTG IgG and/or EM IgG).
- Children with type 1 diabetes detected to have celiac disease on routine screening should be referred to a pediatric gastroenterologist, where available, and on confirmation of the diagnosis receive education and support from an experienced pediatric dietitian. Educational materials for patients and families should be made available (E).
- Diabetes care providers should be alert for the symptoms and signs of Addison's disease (adrenal

- failure) in children and youth with type 1 diabetes although the occurrence is rare (E).
- Prevention of lipohypertrophy includes rotation of injection sites with each injection, using larger injecting zones and non-reuse of needles (E).
 - There is no established therapeutic intervention for lipodystrophy, necrobiosis lipoidica, or limited joint mobility (LJM) (E).
 - Screening for vitamin D deficiency, particularly in high-risk groups, should be considered in young people with type 1 diabetes and treated using appropriate guidelines (E).

Growth, weight gain, and pubertal development

Monitoring of growth and physical development, using appropriate percentile charts and taking mid-parental height into account, are crucial in the care of children and adolescents with diabetes. This includes plotting of anthropometric measurements prior to diagnosis, where available.

Greater height prior to and at diagnosis of type 1 diabetes has been reported frequently (1–7). The precise mechanism for this and whether or not this increased height is maintained is unclear. However, the observation that younger children have the highest BMI suggests pre-natal or early life triggers influence both height and weight gain before diabetes onset (8, 9), as proposed by the ‘accelerator hypothesis’ (10).

There is considerable evidence that patients with suboptimal glycemic control show a decrease in height velocity, while better controlled patients maintain their height advantage (11–13). Insulin is a major regulator of the growth hormone (GH)/insulin-like growth factors (IGFs) axis; adequate insulin secretion and normal portal insulin concentrations are needed to maintain normal serum concentrations of IGFs and IGF-binding proteins, and to promote growth (14). The use of multiple daily insulin injection regimens, insulin analogs, and new technologies including insulin pumps have led to more physiological circulating insulin concentrations, thus improving GH/IGFs alterations (14) and height outcomes, independent of glycemic control (15). The effect of poor glycemic control on growth appears to be exacerbated during puberty, a time of physiological insulin resistance.

Mauriac syndrome, characterized by growth failure, hepatomegaly with glycogenic hepatopathy and steatosis, and late pubertal development, is an uncommon complication in children with persistently poorly controlled diabetes (16, 17). Insulin insufficiency, celiac disease, and other gastrointestinal disorders should be considered in this setting.

There is no role for human GH therapy in the poorly growing child with diabetes, unless it is associated with

Other complications and diabetes-associated conditions

GH deficiency (18), however the diagnosis may be hampered by the high levels of GH, low IGF-1 and low GH-binding protein observed in type 1 diabetes (19–24).

Once the child or adolescent has reached a satisfactory weight after diagnosis, excessive weight gain may indicate high energy intake, and this may be related to excessive exogenous insulin. Excessive weight gain is more common during and after puberty, as well as in those with diagnosis of diabetes in puberty (8, 25). The Diabetes Control and Complications Trial and other studies reported increased weight gain as a side effect of intensive insulin therapy with improved glycemic control (12, 25–27). As obesity is a modifiable cardiovascular risk factor, careful monitoring and management of weight gain should be emphasized in diabetes care.

Girls seem to be more at risk of overweight (25), a recognized risk factor for later development of disturbed eating behavior and eating disorders (28, 29). In association with increased weight is also the risk of ovarian hyperandrogenism, hirsutism, and polycystic ovarian syndrome (30–32). In a recent study of hyperandrogenic adolescents with type 1 diabetes, metformin treatment significantly decreased serum androgens compared with placebo. Metformin therapy did not, however, significantly affect clinical parameters, such as hirsutism, ovulation, and glycemic control; but therapy duration of only 9 months is generally thought to not be long enough to impact on hirsutism (33, 34).

As increased doses of insulin are usually required during puberty, it is important to remember to reduce the dose when IGF-1 levels and insulin requirements decline, typically in late adolescence or young adulthood (24, 35).

Associated autoimmune conditions

Diabetes-associated autoantibodies, including islet cell antibodies (ICA), insulin autoantibodies (IAA), glutamic acid decarboxylase (GAD65), the protein tyrosine phosphatase related molecules IA-2 (ICA512) and IA-2B (phogrin), and/or zinc transporter-8 (ZnT-8) are observed in the overwhelming majority of children *en route* to clinical type 1 diabetes (36). A higher proportion of children with type 1 diabetes have also other detectable organ-specific autoantibodies (e.g., thyroid and adrenal) than children from the general population (37–39). GAD and ZnT8A antibodies are associated with thyroid autoimmunity (38).

Family members of children with diabetes are more likely to have autoantibodies and other manifestations of autoimmune disease than the general population (40–42).

Hypothyroidism

Thyroid disease is one of the most common autoimmune diseases in children with type 1 diabetes,

the other being celiac disease. Thyroid disease occurs more frequently in children and adults with type 1 diabetes than in the general population. Primary or subclinical hypothyroidism due to autoimmune thyroiditis occurs in approximately 3–8% of young people with type 1 diabetes (43, 44), with an incidence ranging from 0.3 to 1.1 per 100 patient years (44, 45) of children and adolescents with diabetes. Antithyroid antibodies can be detected in up to 29% of individuals during the first years of type 1 diabetes (37, 44), and are strongly predictive for the development of hypothyroidism, with a risk ratio of approximately 25 (44, 46). Thyroid antibodies are observed more frequently in girls than in boys, often emerging along with pubertal maturation (44) and also associated with age and diabetes duration (44, 46).

Clinical features may include the presence of a painless goiter, increased weight gain, retarded growth, tiredness, lethargy, cold intolerance, dyslipidemia and bradycardia (43). Glycemic control may not be significantly affected.

Hypothyroidism is confirmed by demonstrating a low free thyroxine and a raised TSH concentration. Importantly, compensated hypothyroidism may be detected in an asymptomatic individual with a normal thyroxine level and a modestly increased TSH.

Treatment of thyroid disease in type 1 diabetes is the same as that used in the general population and is based on replacement with oral L-thyroxine (T4) sufficient to normalize TSH levels. This may allow regression of goiter, if present.

Hyperthyroidism

Hyperthyroidism is less common than hypothyroidism in association with type 1 diabetes, with a reported prevalence of 3–6% in children (44), but is still more common than in the general population. It may be due to Graves' disease or the hyperthyroid phase of Hashimoto's thyroiditis.

Hyperthyroidism should be considered if there is unexplained difficulty in maintaining glycemic control, weight loss without loss of appetite, agitation, tachycardia, tremor, heat intolerance, thyroid enlargement, or characteristic eye signs.

Hyperthyroidism is treated with anti-thyroid drugs such as carbimazole or propylthiouracil; carbimazole is the preferred treatment in children due to the increased risk of liver failure in patients treated with propylthiouracil (47). Beta-adrenergic blocking drugs are helpful during the acute phase of thyrotoxicosis to control tachycardia and agitation. Treatment options for persistent or recurrent hyperthyroidism include surgery or radioactive iodine.

Celiac disease

The prevalence of celiac disease ranges from 1–10% of children and adolescents with diabetes with an incidence of approximately 8 per 1000 patients per year (45, 48–51). The risk of celiac disease is inversely and independently associated with age at diagnosis of diabetes, with the greatest risk in those with diabetes diagnosed before 5 yr of age (50–52). While a large proportion of cases of celiac disease are diagnosed within 2 yr after diabetes presentation and the majority within 10 yr of screening in the pediatric setting, the diagnosis can be made beyond this period (48, 51).

Celiac disease is often asymptomatic (48) and not necessarily associated with poor growth or poor diabetes control (although it should be excluded in such situations). Any child with gastrointestinal signs or symptoms including chronic or intermittent diarrhea and/or constipation, chronic abdominal pain/distention, flatulence, anorexia, dyspeptic symptoms, unexplained poor growth, weight loss, recurrent aphthous ulceration, or anemia should be investigated (50). Undiagnosed celiac disease has also been associated with increased frequency of hypoglycemic episodes and a progressive reduction in insulin requirement over a 12-month period prior to diagnosis (53).

Screening for celiac disease is based on the detection of IgA antibodies (tTG-A and/or EMA); both tests demonstrate sensitivity and specificity >90% (45). Antibodies against deamidated forms of gliadin peptides may also improve the specificity of testing for celiac disease (55). Laboratories reporting celiac disease-specific antibody test results for diagnostic use should continuously participate in quality control programs at a national or international level. Recent guidelines recommend testing for HLA-DQ2 and HLA-DQ8 because celiac disease is unlikely if both haplotypes are negative (56). Adding non-human leukocyte antigen (non-HLA)-susceptible variants to common HLA testing can further improve celiac disease risk prediction (57). However, in people with diabetes, the type 1 diabetes risk alleles (DR3 and DR4) are in linkage disequilibrium with DQ2 and DQ8 and therefore HLA genotyping is likely to exclude celiac disease in only a small proportion of patients (58).

IgA deficiency (which is present in 1:500 in the general population) is more common in people with type 1 diabetes and those with celiac disease (59). Therefore some guidelines recommend routine measurement of total IgA to exclude IgA deficiency, while an alternative strategy is to measure IgA only if the initial screening test using tTG-A and/or EmA is negative. If the child is IgA deficient, IgG-specific antibody tests (tTG or EM IgG, or both) need to be used for screening. This is important because celiac

Other complications and diabetes-associated conditions

disease may be more common in those with IgA deficiency than in the general population (60).

In the presence of an elevated antibody level, a small bowel biopsy is needed to confirm the diagnosis of celiac disease by demonstrating subtotal villus atrophy, as outlined in the Marsh Classification (61). For symptomatic children with high tTG-A titers (>10 times the upper limit of normal), recent guidelines recommend that celiac disease can be diagnosed without duodenal biopsy, if the endomysial IgA level is also positive and the patient carries HLA DQ2 or DQ8 (56, 62). Such a change in practice, which is inconsistent with other guidelines (63), will require prospective evaluation to become generally accepted.

A gluten-free diet normalizes the bowel mucosa and frequently leads to disappearance of antibodies, but may not necessarily lead to improved glycemic control (50, 64). The aims of the gluten-free diet include reduction of the risk of subsequent gastrointestinal malignancy and conditions associated with subclinical malabsorption (osteoporosis, iron deficiency, and growth failure) (50, 65, 66). Long-standing celiac disease may be associated with an increased risk of retinopathy (67), while non-adherence to a gluten free diet may increase the risk of microalbuminuria (68).

Children with proven celiac disease should be referred to a pediatric gastroenterologist, where available, and receive education and support from an experienced pediatric dietitian. Educational materials for patients and families should be made available.

Vitiligo

Vitiligo is an acquired pigmentary disorder characterized by a loss of melanocytes resulting in white spots or leukoderma (69). It is a common autoimmune condition associated with type 1 diabetes and is present in approximately 1–7% of people with type 1 diabetes (70). Treatment is difficult and multiple therapies have been tried with little success. Patients should be advised to avoid the sun and to use broad-spectrum sunscreen. As vitamin D deficiency is common in people with vitiligo, measurement of 25-hydroxyvitamin D levels and supplementation should be considered (71). For localized vitiligo, topical corticosteroids may be effective.

Primary adrenal insufficiency (Addison's disease)

Up to 2% of patients with type 1 diabetes have detectable anti-adrenal autoantibodies (37, 72, 73). The HLA DRB1*04-DQB1*0302 (primarily DRB1*0404) and DRB1*0301-DQB1*0201 haplotypes define high-risk subjects for adrenal autoimmunity (74), while homozygosity for the major histocompatibility complex (MHC) (HLA) class I chain-related gene A

(MICA) polymorphism 5.1 defines those at highest risk for progression to overt Addison's disease (75). Addison's disease may be associated with type 1 diabetes as part of the autoimmune polyglandular syndromes (APS-1 and APS-2) (76). APS 1, also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), often presents in childhood and is characterized by the development of adrenal insufficiency, chronic mucocutaneous candidiasis, and hypoparathyroidism. It is caused by a mutation in the autoimmune regulator gene (AIRE) on chromosome at chromosome 21q22.3 (77, 78). In APS-2 (also known as Schmidt Syndrome), the combination of adrenal insufficiency and type 1 diabetes is more common not only in adults (79), but is also seen in children in association with autoimmune thyroiditis (80).

Addison's disease is suspected by the clinical picture of frequent hypoglycemia, unexplained decrease in insulin requirements, increased skin pigmentation, lassitude, weight loss, hyponatremia, and hyperkalemia. The diagnosis is based on the demonstration of a low cortisol response to stimulation with Adrenocorticotropic hormone (ACTH) and evaluation for the presence of adrenal antibodies, although a negative antibody result does not exclude adrenal pathology. Treatment with a glucocorticoid is urgent and lifelong. In some cases the therapy has to be supplemented with a mineralocorticoid such as fludrocortisone.

In asymptomatic children with positive adrenal antibodies detected on routine screening, a rising ACTH level suggests a failing adrenal cortex and the development of primary adrenal insufficiency.

The immunodysregulation polyendocrinopathy X-linked syndrome (IPEX) is another rare disorder associated with diabetes in early childhood, severe enteropathy, and autoimmune symptoms due to a mutation in the forkhead box P3 (*FOX-P3*) gene, which encodes a transcription factor essential for the development and function of regulatory T cells (81, 82).

Lipodystrophy (lipoatrophy and lipohypertrophy)

Lipoatrophy is now seen infrequently with the use of human insulin, and is reported in <1% of patients with type 1 diabetes (83). Case reports have described lipoatrophy in patients treated with insulin analogs, including lispro, glargin, aspart, and detemir (84–86), but it is still a rare side effect. Lipoatrophy has also been described in association with Hashimoto's thyroiditis and celiac disease; the authors speculated that an immune complex-mediated inflammation may contribute to the development of lipoatrophy (87).

Lipohypertrophy is a frequent complication of insulin therapy. Its detection requires both visualization and palpation of injecting sites, as some lesions

can be more easily felt than seen. Normal skin can be pinched tightly together, while lipohypertrophy cannot (88). Lipohypertrophy has been found in up to 48% of those with type 1 diabetes and is associated with higher hemoglobin A1c (HbA1c), greater number of injections, and longer duration of diabetes (83, 89, 90). Lack of rotation of injection sites, use of small injection zones and reusing needles have been consistently reported as independent risk factors for lipohypertrophy (88, 89), while needle length does not have a recognized association. Not only is it unsightly, but insulin may be absorbed erratically and unpredictably from these areas, affecting blood glucose control (91). Treatment of lipohypertrophy involves avoidance of the affected sites for at least 2–3 months, while prevention strategies include rotation of injection sites with each injection, using larger injecting zones and non-reuse of needles.

Necrobiosis lipoidica diabetorum

These are well circumscribed, raised reddish lesions sometimes progressing to central ulceration, usually seen in the pretibial region. The reported prevalence in children varies from 0.06 to 1.6% (92, 93). The etiology is not clearly understood but microangiopathy is thought to play a significant role (93). Necrobiosis lipoidica has been associated with underlying microvascular complications including retinopathy and nephropathy (94, 95). A wide variety of treatments have been used, mostly in adults and with limited efficacy, including: topical, systemic or intra-lesional steroids, aspirin (with or without dipyridamole), cyclosporin, mycophenolate, nicotinic acid, excision and grafting, laser surgery, hyperbaric oxygen, topical granulocyte macrophage colony-stimulating factor, and photochemotherapy with topical Psoralen plus ultraviolet A light (PUVA) (93, 96). Few of the treatment have been evaluated in randomized controlled trials and many have significant side effects (93).

Limited joint mobility

LJM is a bilateral painless, but obvious, contracture of the finger joints and large joints, associated with tight waxy skin. Following its initial description in the 1970s in association with short stature and early microvascular complications, it was observed as a common feature of type 1 diabetes (97, 99). However, more recent studies indicate LJM is present in a minority (~4%) of adolescents with type 1 diabetes (100). There was a >4 fold reduction in frequency of LJM between the mid-70s and mid-90s, in children (101) and a lesser decline in adults (102), with a marked decrease in severity in the fewer children who were affected, most likely the result of improved glucose control during this era.

A simple examination method is to have the patient attempt to approximate palmar surfaces of the interphalangeal joints (103). Passive examination is essential to confirm that inability to do so is due to LJM. With rare exception, LJM appears after the age of 10 yr. The interval between the detection of mild LJM and progression to moderate or severe changes in those who progress beyond mild changes, ranges from a few months to 4 yr, following which stabilization occurs (86).

Skin biopsy specimens have shown active fibroblasts and extensive collagen polymerization in the rough endoplasmic reticulum (104). The biochemical basis for LJM is likely glycation of protein with the formation of advanced glycation end products (AGE). This results in increased stiffness of the periarticular and skin collagen with decreased range of motion. Fluorescence of skin collagen, reflecting the accumulation of stable end products of the glycation reaction, with increased crosslinking, dehydration, and condensation of collagen, increases linearly with age but with abnormal rapidity in type 1 diabetes and is correlated with the presence of retinopathy, nephropathy, vascular disease and LJM (105, 106).

Similarly, LJM is associated with a twofold to four-fold risk for retinopathy, nephropathy, and neuropathy (98, 99, 107). Although cross-sectional studies showed no relationship to glycemic control as measured by HbA1c, a longitudinal study of average HbA1c from onset of diabetes showed that for every unit increase in average HbA1c, there was an approximately 46% increase in the risk of developing LJM (108).

Edema

Generalized edema due to water retention is a rare complication of insulin therapy, particularly in young people (109, 105). Edema may be seen during establishment of improved glycemic control after initial diagnosis and after prolonged periods of poor metabolic control, particularly if there has been significant omission of insulin (111). The edema spontaneously resolves over a period of days to weeks with continued good glycemic control. In severe cases, ephedrine has been an effective treatment (112).

Bone health

Type 1 diabetes is associated with osteoporosis and an increased fracture risk, although data in young people with type 1 diabetes are limited (113). Abnormal bone accrual (density and quality) in type 1 diabetes likely has a multifactorial etiology, involving reduced bone formation and abnormal bone quality (114). Two major determinants of bone strain in children are muscle pull and growth. Insulin is anabolic to muscle as well as bone, with many of the factors

Other complications and diabetes-associated conditions

detrimental to bone development potentially impacting on muscle or the relationship between muscle and bone. Comorbidities such as celiac disease and thyroid dysfunction can also negatively affect bone health in type 1 diabetes, but the true extent of their impact in children and adolescents is unclear. Therefore, assessment of bone health using bone densitometry should be considered in late adolescence in youth with long duration of type 1 diabetes, especially if complicated by celiac disease. Screening for vitamin D deficiency, particularly in high-risk groups, should be considered in young people with type 1 diabetes and treated using appropriate guidelines (115, 116).

Acknowledgement

We are thankful to Assoc. Prof. Craig Munns, The Children's Hospital at Westmead, Sydney Australia for his contribution to this work.

Conflicts of interest

The authors have declared no conflicts of interest.

References

1. BOGNETTI E, RIVA MC, BONFANTI R, MESCHI F, VISCARDI M, CHIUMELLO G. Growth changes in children and adolescents with short-term diabetes. *Diabetes Care* 1998; 21: 1226–1229.
2. LJUNGKRANTZ M, LUDVIGSSON J, SAMUELSSON U. Type 1 diabetes: increased height and weight gains in early childhood. *Pediatr Diabetes* 2008; 9: 50–56.
3. LAMB MM, YIN X, ZERBE GO et al. Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young. *Diabetologia* 2009; 52: 2064–2071.
4. VEHIK K, HAMMAN RF, LEZOTTE D, NORRIS JM, KLINGENSMITH GJ, DABELEA D. Childhood growth and age at diagnosis with type 1 diabetes in Colorado young people. *Diabet Med* 2009; 26: 961–967.
5. ISLAM ST, ABRAHAM A, DONAGHUE KC et al. Plateau of adiposity in Australian children diagnosed with type 1 diabetes: a 20-year study. *Diabet Med* 2014; 31(6):686–690.
6. BEYERLEIN A, THIERING E, PFLUEGER M et al. Early infant growth is associated with the risk of islet autoimmunity in genetically susceptible children. *Pediatr Diabetes* 2014; Feb 21 [epub ahead of print].
7. KNERR I, WOLF J, REINEHR T, STACHOW R, GRABERT M, SCHOBER E, et al. The ‘accelerator hypothesis’: relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9,248 German and Austrian children with type 1 diabetes mellitus. *Diabetologia*. 2005; 48:2501–2504.
8. CLARKE SL, CRAIG ME, GARNETT SP et al. Increased adiposity at diagnosis in younger children with type 1 diabetes does not persist. *Diabetes Care* 2006; 29: 1651–1653.
9. COUPER JJ, BERESFORD S, HIRTE C et al. Weight gain in early life predicts risk of islet autoimmunity in children with a first-degree relative with type 1 diabetes. *Diabetes Care* 2009; 32: 94–99.
10. WILKIN TJ. The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. *Int J Obes (Lond)*. 2009; 33:716–726.
11. GUNCZLER P, LANES R. Poor metabolic control decreases the growth velocity of diabetic children. *Diabetes Care*. 1999; 22:1012.
12. DOWNIE E, CRAIG ME, HING S, CUSUMANO J, CHAN AK, DONAGHUE KC. Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control. *Diabetes Care* 2011; 34: 2368–2373.
13. BONFIG W, KAPELLEN T, DOST A et al. Growth in children and adolescents with type 1 diabetes. *J Pediatr* 2012; 160: 900–3.e2.
14. GIANNINI C, MOHN A, CHIARELLI F. Growth abnormalities in children with type 1 diabetes, juvenile chronic arthritis, and asthma. *Int J Endocrinol* 2014; 2014: 265954.
15. DONAGHUE KC, KORDONOURI O, CHAN A, SILINK M. Secular trends in growth in diabetes: are we winning? *Arch Dis Child* 2003; 88: 151–154.
16. FITZPATRICK E, COTOI C, QUAGLIA A, SAKELLARIOU S, FORD-ADAMS ME, HADZIC N. Hepatopathy of Mauriac syndrome: a retrospective review from a tertiary liver centre. *Arch Dis Child* 2014; 99: 354–357.
17. KIM MS, QUINTOS JB. Mauriac syndrome: growth failure and type 1 diabetes mellitus. *Pediatr Endocrinol Rev* 2008; 5 (Suppl. 4): 989–993.
18. BONFIG W, MOLZ K, WOELFLE J, HOFER SE, HAUFFA BP, SCHOENAU E, et al. Metabolic safety of growth hormone in type 1 diabetes and idiopathic growth hormone deficiency. *J Pediatr*. 2013; 163:1095–8 e4.
19. EDGE JA, DUNGER DB, MATTHEWS DR, GILBERT JP, SMITH CP. Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. *J Clin Endocrinol Metab*. 1990; 71:1356–1362.
20. HOLL RW, SIEGLER B, SCHERBAUM WA, HEINZE E. The serum growth hormone-binding protein is reduced in young patients with insulin-dependent diabetes mellitus. *J Clin Endocrinol Metab*. 1993; 76:165–167.
21. HEDMAN CA, FRYSTYK J, LINDSTRÖM T, CHEN JW, FLYVBJERG A, ØRSKOV H, et al. Residual beta-cell function more than glycemic control determines abnormalities of the insulin-like growth factor system in type 1 diabetes. *J Clin Endocrinol Metab*. 2004; 89:6305–6319.
22. CLEMMONS DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. *Endocrinol Metab Clin North Am*. 2012; 41:425–443, vii–viii.
23. KIM MS, LEE DY. Serum insulin-like growth factor-binding protein-3 level correlated with glycemic control and lipid profiles in children and adolescents with type 1 diabetes. *J Pediatr Endocrinol Metab*. 2014.
24. PALTA M, LECAIRE T, SADEK-BADAWI M, HERRERA V, DANIELSON KK. The trajectory of IGF-1 across age and duration of type 1 diabetes. *Diabetes Metab Res Rev*. 2014.
25. FRÖHLICH-REITERER EE, ROSENBAUER J, BECHTOLD-DALLA POZZA S et al. Predictors of increasing BMI during the course of diabetes in children and adolescents with type 1 diabetes: data from the

- German/Austrian DPV multicentre survey. *Arch Dis Child* 2014; May 8 [epub ahead of print].
26. DCCT Research Group (Diabetes Control and Complications Trial Research Group). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993; 329: 977–986.
 27. HOLL RW, GRABERT M, SORGO W, HEINZE E, DEBATIN KM. Contributions of age, gender and insulin administration to weight gain in subjects with IDDM. *Diabetologia* 1998; 41: 542–547.
 28. OLMSTED MP, COLTON PA, DANEMAN D, RYDALL AC, RODIN GM. Prediction of the onset of disturbed eating behavior in adolescent girls with type 1 diabetes. *Diabetes Care*. 2008; 31:1978–1982.
 29. YOUNG V, EISER C, JOHNSON B, BRIERLEY S, EPTON T, ELLIOTT J, et al. Eating problems in adolescents with Type 1 diabetes: a systematic review with meta-analysis. *Diabet Med*. 2013; 30:189–198.
 30. CODNER E, SOTO N, LOPEZ P et al. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. *J Clin Endocrinol Metab* 2006; 91: 2250–2256.
 31. CODNER E, CASSORLA F. Puberty and ovarian function in girls with type 1 diabetes mellitus. *Horm Res* 2009; 71: 12–21.
 32. CHO YH, CRAIG ME, SRINIVASAN S et al. Heart rate variability in pubertal girls with type 1 diabetes: its relationship with glycaemic control, insulin resistance and hyperandrogenism. *Clin Endocrinol (Oxf)* 2014; 80: 818–824.
 33. CODNER E, IÑIGUEZ G, LÓPEZ P et al. Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. *Horm Res Paediatr* 2013; 80: 343–349.
 34. NATHAN N, SULLIVAN SD. The utility of metformin therapy in reproductive-aged women with polycystic ovary syndrome (PCOS). *Curr Pharm Biotechnol* 2014; Mar 30 [Epub ahead of print].
 35. WATKINS RA, EVANS-MOLINA C, BLUM JS, DIMEGLIO LA. Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review. *Transl Res* 2014; Mar 4. pii: S1931-5244(14)00078-4.
 36. WATKINS RA, EVANS-MOLINA C, BLUM JS, DIMEGLIO LA. Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review. *Transl Res*. 2014.
 37. WARNCKE K, FROHLICH-REITERER EE, THON A, HOFER SE, WIEMANN D, HOLL RW. Polyendocrinopathy in children, adolescents, and young adults with type 1 diabetes: a multicenter analysis of 28,671 patients from the German/Austrian DPV-Wiss database. *Diabetes Care* 2010; 33: 2010–2012.
 38. JONSDOTTIR B, ANDERSSON C, CARLSSON A et al. Thyroid autoimmunity in relation to islet autoantibodies and HLA-DQ genotype in newly diagnosed type 1 diabetes in children and adolescents. *Diabetologia* 2013; 56: 1735–1742.
 39. ZHERNAKOVA A, WITHOFF S, WIJMENGA C. Clinical implications of shared genetics and pathogenesis in autoimmune diseases. *Nat Rev Endocrinol* 2013; 9: 646–659.
 40. SUMNIK Z, KOLOUSKOVA S, MALCOVA H et al. High prevalence of coeliac disease in siblings of children with type 1 diabetes. *Eur J Pediatr* 2005; 164: 9–12.
 41. MOHN A, DI MICHELE S, FARICELLI R, MARTINOTTI S, CHIARELLI F. Increased frequency of subclinical hypothyroidism and thyroid-associated antibodies in siblings of children and adolescents with type 1 diabetes mellitus. *Eur J Endocrinol* 2005; 153: 717–718.
 42. SOSENKO JM, SKYLER JS, PALMER JP et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. *Diabetes Care* 2013; 36: 2615–2620.
 43. DENZER C, KARGES B, NÄKE A et al. Subclinical hypothyroidism and dyslipidemia in children and adolescents with type 1 diabetes mellitus. *Eur J Endocrinol* 2013; 168: 601–608.
 44. SHUN CB, DONAGHUE KC, PHelan H, TWIGG SM, CRAIG ME. Thyroid autoimmunity in type 1 diabetes: systematic review and meta-analysis. *Diabet Med* 2014; 31: 126–135.
 45. GLASTRAS SJ, CRAIG ME, VERGE CF, CHAN AK, CUSUMANO JM, DONAGHUE KC. The role of autoimmunity at diagnosis of type 1 diabetes in the development of thyroid and celiac disease and microvascular complications. *Diabetes Care* 2005; 28: 2170–2175.
 46. KORDONOURI O, HARTMANN R, DEISS D, WILMS M, GRUTERS-KIESLICH A. Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty. *Arch Dis Child* 2005; 90: 411–414.
 47. RIVKEES SA, MATTISON DR. Ending propylthiouracil-induced liver failure in children. *N Engl J Med* 2009; 360: 1574–1575.
 48. LARSSON K, CARLSSON A, CEDERWALL E et al. Annual screening detects celiac disease in children with type 1 diabetes. *Pediatr Diabetes* 2008; 9: 354–359.
 49. SALARDI S, VOLTA U, ZUCCHINI S et al. Prevalence of celiac disease in children with type 1 diabetes mellitus increased in the mid-1990s: an 18-year longitudinal study based on anti-endomysial antibodies. *J Pediatr Gastroenterol Nutr* 2008; 46: 612–614.
 50. FRÖHLICH-REITERER EE, KASPERS S, HOFER S et al. Anthropometry, metabolic control, and follow-up in children and adolescents with type 1 diabetes mellitus and biopsy-proven celiac disease. *J Pediatr* 2011; 158: 589–93.e2.
 51. PHAM-SHORT A, DONAGHUE KC, AMBLER G, CHAN AK, CRAIG ME. Coeliac disease in type 1 diabetes from 1990 to 2009: higher incidence in young children after longer diabetes duration. *Diabet Med* 2012; 29: e286–e289.
 52. CERUTTI F, CHIARELLI F, LORINI R, MESCHI F, SACCHETTI C. Younger age at onset and sex predict celiac disease in children and adolescents with type 1 diabetes. *Diabetes Care* 2004; 27: 1294–1298.
 53. MOHN A, CERRUTO M, IAFUSCO D et al. Celiac disease in children and adolescents with type 1 diabetes: importance of hypoglycemia. *J Pediatr Gastroenterol Nutr* 2001; 32: 37–40.
 54. GIERSIEPEN K, LELGEMANN M, STUHLDREHER N et al. Accuracy of diagnostic antibody tests for coeliac disease in children: summary of an evidence report. *J Pediatr Gastroenterol Nutr* 2012; 54: 229–241.

Other complications and diabetes-associated conditions

55. MOTHES T. Deamidated gliadin peptides as targets for celiac disease-specific antibodies. *Adv Clin Chem* 2007; 44: 35–63.
56. HUSBY S, KOLETZKO S, KORPONAY-SZABÓ IR et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. *J Pediatr Gastroenterol Nutr* 2012; 54: 136–160.
57. ROMANOS J, ROSÉN A, KUMAR V et al. Improving coeliac disease risk prediction by testing non-HLA variants additional to HLA variants. *Gut* 2014; 63: 415–422.
58. DOOLAN A, DONAGHUE K, FAIRCHILD J, WONG M, WILLIAMS AJ. Use of HLA typing in diagnosing celiac disease in patients with type 1 diabetes. *Diabetes Care*. 2005; 28:806–819.
59. KURIEN M, LEEDS JS, HOPPER AD et al. Serological testing for coeliac disease in type 1 diabetes mellitus: is immunoglobulin A level measurement necessary? *Diabet Med* 2013; 30: 840–845.
60. CATALDO F, MARINO V, BOTTARO G, GRECO P, VENTURA A. Celiac disease and selective immunoglobulin A deficiency. *J Pediatr* 1997; 131: 306–308.
61. MARSH MN, CROWE PT. Morphology of the mucosal lesion in gluten sensitivity. *Baillieres Clin Gastroenterol* 1995; 9: 273–293.
62. MURCH S, JENKINS H, AUTH M et al. Joint BSPGHAN and Coeliac UK guidelines for the diagnosis and management of coeliac disease in children. *Arch Dis Child* 2013; 98: 806–811.
63. RUBIO-TAPIA A, HILL ID, KELLY CP, CALDERWOOD AH, MURRAY JA. Gastroenterology ACo. ACG clinical guidelines: diagnosis and management of celiac disease. *Am J Gastroenterol* 2013; 108: 656–676; quiz 77.
64. AMIN R, MURPHY N, EDGE J, AHMED ML, ACERINI CL, DUNGER DB. A longitudinal study of the effects of a gluten-free diet on glycemic control and weight gain in subjects with type 1 diabetes and celiac disease. *Diabetes Care* 2002; 25: 1117–1122.
65. SAUKKONEN T, VAISANEN S, AKERBLOM HK, SAVILAHTI E. Coeliac disease in children and adolescents with type 1 diabetes: a study of growth, glycaemic control, and experiences of families. *Acta Paediatr* 2002; 91: 297–302.
66. MARGONI D, CHOULIARAS G, DUSCAS G et al. Bone health in children with celiac disease assessed by dual x-ray absorptiometry: effect of gluten-free diet and predictive value of serum biochemical indices. *J Pediatr Gastroenterol Nutr* 2012; 54: 680–684.
67. MOLLAZADEGAN K, KUGELBERG M, MONTGOMERY SM, SANDERS DS, LUDVIGSSON J, LUDVIGSSON JF. A population-based study of the risk of diabetic retinopathy in patients with type 1 diabetes and celiac disease. *Diabetes Care* 2013; 36: 316–321.
68. PHAM-SHORT A, DONAGHUE CK, AMBLER G et al. Early elevation of albumin excretion rate is associated with poor gluten-free diet adherence in young people with coeliac disease and diabetes. *Diabet Med* 2014; 31: 208–212.
69. HANNA S, DOGRA S. Epidemiology of childhood vitiligo: a study of 625 patients from north India. *Pediatr Dermatol* 2003; 20: 207–210.
70. VAN HATTEM S, BOOTSMA AH, THIO HB. Skin manifestations of diabetes. *Cleve Clin J Med* 2008; 75: 772, 774, 776–777 passim.
71. SALEH HM, ABDEL FATTAH NS, HAMZA HT. Evaluation of serum 25-hydroxyvitamin D levels in vitiligo patients with and without autoimmune diseases. *Photodermatol Photoimmunol Photomed* 2013; 29: 34–40.
72. PETERSON P, SALMI H, HYÖTY H et al. Steroid 21-hydroxylase autoantibodies in insulin-dependent diabetes mellitus. *Childhood Diabetes in Finland (DiMe) Study Group. Clin Immunol Immunopathol* 1997; 82: 37–42.
73. DE BLOCK CE, DE LEEUW IH, VERTOMMEN JJ et al. Beta-cell, thyroid, gastric, adrenal and coeliac autoimmunity and HLA-DQ types in type 1 diabetes. *Clin Exp Immunol* 2001; 126: 236–241.
74. BAKER P, FAIN P, KAHLES H et al. Genetic determinants of 21-hydroxylase autoantibodies amongst patients of the type 1 diabetes Genetics Consortium. *J Clin Endocrinol Metab* 2012; 97: E1573–E1578.
75. TRIOLI TM, BASCHAL EE, ARMSTRONG TK et al. Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes. *J Clin Endocrinol Metab* 2009; 94: 4517–4523.
76. CUTOLO M. Autoimmune polyendocrine syndromes. *Autoimmun Rev* 2014; 13: 85–89.
77. AALTONEN J, BJÖRSÉS P, SANDKUIJL L, PERHEENTUPA J, PELTONEN L. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type I assigned to chromosome 21. *Nat Genet* 1994; 8: 83–87.
78. AHONEN P, MYLLÄRNIEMI S, SIPILÄ I, PERHEENTUPA J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. *N Engl J Med* 1990; 322: 1829–1836.
79. BRANDÃO NETO RA, DE CARVALHO JF. Diagnosis and classification of Addison's disease (autoimmune adrenalitis). *Autoimmun Rev* 2014; 13: 408–411.
80. DITTMAR M, KAHALY GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. *J Clin Endocrinol Metab* 2003; 88: 2983–2992.
81. MICHELS AW, GOTTLIEB PA. Autoimmune polyglandular syndromes. *Nat Rev Endocrinol* 2010; 6: 270–277.
82. ODA JM, HIRATA BK, GUEMBAROVSKI RL, WATANABE MA. Genetic polymorphism in FOXP3 gene: imbalance in regulatory T-cell role and development of human diseases. *J Genet* 2013; 92: 163–171.
83. SAWATKAR GU, KANWAR AJ, DOGRA S, BHADADA SK, DAYAL D. Spectrum of cutaneous manifestations of type 1 diabetes mellitus in 500 south Asian patients. *Br J Dermatol* 2014; doi: 10.1111/bjd.13077. Apr 28. [Epub ahead of print].
84. GRIFFIN ME, FEDER A, TAMBORLANE WV. Lipotrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause? *Diabetes Care* 2001; 24: 174.
85. AMPUDIA-BLASCO FJ, GIRBES J, CARMENA R. A case of lipotrophy with insulin glargine: long-acting insulin analogs are not exempt from this complication. *Diabetes Care* 2005; 28: 2983.

86. BABIKER A, DATTA V. Lipoatrophy with insulin analogues in type I diabetes. *Arch Dis Child* 2011; 96: 101–102.
87. SALGIN B, MEISSNER T, BEYER P et al. Lipoatrophy is associated with an increased risk of Hashimoto's thyroiditis and coeliac disease in female patients with type 1 diabetes. *Horm Res Paediatr* 2013; 79: 368–372.
88. FRID A, HIRSCH L, GASPAR R et al. New injection recommendations for patients with diabetes. *Diabetes Metab* 2010; 36 (Suppl. 2): S3–S18.
89. HAUNER H, STOCKAMP B, HAASTERT B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. *Exp Clin Endocrinol Diabetes* 1996; 104: 106–110.
90. KORDONOURI O, LAUTERBORN R, DEISS D. Lipohypertrophy in young patients with type 1 diabetes. *Diabetes Care* 2002; 25: 634.
91. JOHANSSON UB, AMSBERG S, HANNERZ L et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. *Diabetes Care* 2005; 28: 2025–2027.
92. DE SILVA BD, SCHOFIELD OM, WALKER JD. The prevalence of necrobiosis lipoidica diabetorum in children with type 1 diabetes. *Br J Dermatol* 1999; 141: 593–594.
93. REID SD, LADIZINSKI B, LEE K, BAIBERGENOVA A, ALAVI A. Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. *J Am Acad Dermatol* 2013; 69: 783–791.
94. KELLY WF, NICHOLAS J, ADAMS J, MAHMOOD R. Necrobiosis lipoidica diabetorum: association with background retinopathy, smoking, and proteinuria. A case controlled study. *Diabet Med* 1993; 10: 725–728.
95. VERROTTI A, CHIARELLI F, AMERIO P, MORGESE G. Necrobiosis lipoidica diabetorum in children and adolescents: a clue for underlying renal and retinal disease. *Pediatr Dermatol* 1995; 12: 220–223.
96. ERFURT-BERGE C, SEITZ AT, REHSE C, WOLLINA U, SCHWEDE K, RENNER R. Update on clinical and laboratory features in necrobiosis lipoidica: a retrospective multicentre study of 52 patients. *Eur J Dermatol* 2012; 22: 770–775.
97. GRGIC A, ROSENBLoom AL, WEBER FT, GIORDANO B, MALONE JI, SHUSTER JJ. Joint contracture – common manifestation of childhood diabetes mellitus. *J Pediatr* 1976; 88: 584–588.
98. ROSENBLoom AL, SILVERSTEIN JH, LEZOTTE DC, RILEY WJ, MACLAREN NK. Limited joint mobility in diabetes mellitus of childhood: natural history and relationship to growth impairment. *J Pediatr* 1982; 101: 874–878.
99. DUFFIN AC, DONAGHUE KC, POTTER M, MCINNES A, CHAN AK, KING J, et al. Limited joint mobility in the hands and feet of adolescents with Type 1 diabetes. *Diabetic Medicine*. 1999; 16:125–130.
100. CRAIG ME, DUFFIN AC, GALLEGOS PH, LAM A, CUSUMANO J, HING S, et al. Plantar fascia thickness, a measure of tissue glycation, predicts the development of complications in adolescents with type 1 diabetes. *Diabetes Care*. 2008; 31:1201–1206.
101. INFANTE JR, ROSENBLoom AL, SILVERSTEIN JH, GARZARELLA L, POLLOCK BH. Changes in frequency and severity of limited joint mobility in children with type 1 diabetes mellitus between 1976–78 and 1998. *J Pediatr*. 2001; 138:33–37.
102. LINDSAY JR, KENNEDY L, ATKINSON AB, BELL PM, CARSON DJ, McCANCE DR, et al. Reduced prevalence of limited joint mobility in type 1 diabetes in a U.K. clinic population over a 20-year period. *Diabetes Care*. 2005; 28:658–661.
103. ROSENBLoom AL, SILVERSTEIN JH, LEZOTTE DC, RICHARDSON K, McCALLUM M. Limited joint mobility in childhood diabetes mellitus indicates increased risk for microvascular disease. *N Engl J Med* 1981; 305: 191–194.
104. HANNA W, FRIESEN D, BOMBARDIER C, GLADMAN D, HANNA A. Pathologic features of diabetic thick skin. *J Am Acad Dermatol* 1987; 16: 546–553.
105. MONNIER VM, VISHWANATH V, FRANK KE, ELMETS CA, DAUCHOT P, KOHN RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. *N Engl J Med* 1986; 314: 403–408.
106. CONWAY BN, ARODA VR, MAYNARD JD, MATTER N, FERNANDEZ S, RATNER RE, et al. Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes. *Diabetes Care*. 2012; 35:2331–2336.
107. GARG SK, CHASE HP, MARSHALL G et al. Limited joint mobility in subjects with insulin dependent diabetes mellitus: relationship with eye and kidney complications. *Arch Dis Child* 1992; 67: 96–99.
108. SILVERSTEIN JH, GORDON G, POLLOCK BH, ROSENBLoom AL. Long-term glycemic control influences the onset of limited joint mobility in type 1 diabetes. *J Pediatr* 1998; 132: 944–947.
109. ARAVAMUDHAN A, GARDNER C, SMITH C, SENNIAPPAN S. Insulin oedema in a child with newly diagnosed diabetes mellitus. *Eur J Pediatr* 2014; 173: 685–687.
110. BAŞ VN, ÇETINKAYA S, AĞLADIOĞLU SY et al. Insulin oedema in newly diagnosed type 1 diabetes mellitus. *J Clin Res Pediatr Endocrinol* 2010; 2: 46–48.
111. HIRSHBERG B, MUSZKAT M, MAROM T, SHALIT M. Natural course of insulin edema. *J Endocrinol Invest* 2000; 23: 187–188.
112. HOPKINS DF, COTTON SJ, WILLIAMS G. Effective treatment of insulin-induced edema using ephedrine. *Diabetes Care* 1993; 16: 1026–1028.
113. VESTERGAARD P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. *Osteoporos Int*. 2007; 18:427–444.
114. WĘDRYCHOWICZ A, STEC M, SZTEFKO K, STARZYK JB. Associations between Bone, Fat Tissue and Metabolic Control in Children and Adolescents with Type 1 Diabetes Mellitus. *Exp Clin Endocrinol Diabetes*. 2014.
115. HOLICK MF, BINKLEY NC, BISCHOFF-FERRARI HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011; 96: 1911–1930.
116. PAXTON GA, TEALE GR, Nowson CA et al. Vitamin D and health in pregnancy, infants, children and adolescents in Australia and New Zealand: a position statement. *Med J Aust* 2013; 198: 142–143.